Literature DB >> 28252263

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Eli Ipp1, Pauline Genter2, Kristin Childress3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28252263     DOI： 10.1056/NEJMc1615712

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.

Authors:  Beini Lyu; Morgan E Grams; Alex Chang; Lesley A Inker; Josef Coresh; Jung-Im Shin
Journal:  Am J Cardiol       Date:  2021-12-20       Impact factor: 2.778

Review 2.  Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management.

Authors:  Cheng-Xu Ma; Xiao-Ni Ma; Cong-Hui Guan; Ying-Dong Li; Dídac Mauricio; Song-Bo Fu
Journal:  Cardiovasc Diabetol       Date:  2022-05-14       Impact factor: 8.949

3.  GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-κB signalling pathway.

Authors:  Xiangheng Chen; Qiuling Huang; Juling Feng; Zhongsheng Xiao; Xiaoling Zhang; Lei Zhao
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

4.  Polyethylene Glycol Loxenatide Injection (GLP-1) Protects Vascular Endothelial Cell Function in Middle-Aged and Elderly Patients With Type 2 Diabetes by Regulating Gut Microbiota.

Authors:  Fengwu Chen; Lina He; Jilin Li; Shuhui Yang; Bangzhou Zhang; Dan Zhu; Zezhen Wu; Shuo Zhang; Ducheng Hou; Cong Ouyang; Jianfeng Yi; Chuanxing Xiao; Kaijian Hou
Journal:  Front Mol Biosci       Date:  2022-06-15

Review 5.  Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics.

Authors:  Miyesaier Abudureyimu; Xuanming Luo; Xiang Wang; James R Sowers; Wenshuo Wang; Junbo Ge; Jun Ren; Yingmei Zhang
Journal:  J Mol Cell Biol       Date:  2022-09-12       Impact factor: 8.185

6.  Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China.

Authors:  Shanshan Hu; Xiaorong Su; Xun Deng; Yong Wang
Journal:  Front Pharmacol       Date:  2021-06-10       Impact factor: 5.810

Review 7.  Postprandial Glucose Spikes, an Important Contributor to Cardiovascular Disease in Diabetes?

Authors:  Nordin M J Hanssen; Michael J Kraakman; Michelle C Flynn; Prabhakara R Nagareddy; Casper G Schalkwijk; Andrew J Murphy
Journal:  Front Cardiovasc Med       Date:  2020-09-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.